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Abstract
Background: Observational HIV clinic databases are now widely used to answer key questions related to HIV care
and treatment, but there has been no systematic evaluation of their quality of data. Our objective was to evaluate
the completeness and accuracy of recording of key data HIV items in a large routine observational HIV clinic
database.
Methods: We looked at the number and rate of opportunistic infections (OIs) per 100 person years at risk in the
24 months following antiretroviral therapy (ART) initiation in 559 patients who initiated ART in 2004-2005 and
enrolled into a research cohort. We compared this with data in a routine clinic database for the same 559 patients,
and a further 1233 patients who initiated ART in the same period. The Research Cohort database was considered
as the reference “gold standard” for the assessment of data accuracy. A crude percentage of underreporting of OIs
in the clinic database was calculated based on the difference between the OI rates reported in both databases.
We reviewed 100 clinic patient medical records to assess the accuracy of recording of key data items of OIs, ART
toxicities and ART regimen changes.
Results: The overall incidence rate per 100 person years at risk for the initial OI in the 559 patients in the research
cohort and clinic databases was 24.1 (95% CI: 20.5-28.2) and 13.2 (95% CI: 10.8-16.2) respectively, and 10.4 (95% CI:
9.1-11.9) for the 1233 clinic patients. This represents a 1.8- and 2.3-fold higher rate of events in the research cohort
database compared with the same 599 patients and 1233 patients in the routine clinic database, or a 45.1% and
56.8% rate of underreporting, respectively. The combined error rate of missing and incorrect items from the
medical records’ review was 67% for OIs, 52% for ART-related toxicities, and 83% and 58% for ART discontinuation
and modification, respectively.
Conclusions: There is a high rate of underreporting of OIs in a routine HIV clinic database. This has important
implications for the use and interpretation of routine observational databases for research and audit, and highlights
the need for regular data validation of these databases.
Background
Prospective research cohorts of HIV-infected persons have
made a major contribution to an understanding of the
transmission, natural history and pathogenesis of HIV
infection [1-3], in addition to generating important
information on the response to and long-term outcomes
with antiretroviral therapy (ART). Distinctive features of
these research cohorts are their voluntary enrolment of
selected eligible patients, prospective follow up and stan-
dardized data collection at regular defined time points.
Their principal disadvantages are that they are costly to
establish and maintain, tend to study selected populations,
and may be poorly representative of the demography and * Correspondence: akiragga@idi.co.ug
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any medium, provided the original work is properly cited.outcomes of the majority of patients currently receiving
ART.
As a result, over the past decade, there has been a
major shift towards the use of local or regional observa-
tional HIV clinic databases to answer key questions
related to HIV care and treatment. These are usually
based on unselected patients in care at a single clinic or
across multiple clinics, and use data collected during the
routine delivery of HIV care [4-6]. Their key advantages
are that they are generally large and representative,
since they are based on all patients in care, and involve
minimal additional resources as a result of using routi-
nely collected data. Their principal limitations are miss-
ing, incomplete or inaccurate data due to either visit
schedules varying according to patient need, or to fail-
ures in either data collection or data entry. Although
some of these databases have quality assurance and
auditing programmes [4,7], there has been no systematic
evaluation of the quality of data in these now widely
used HIV observational databases in different clinical
settings.
The Infectious Diseases Institute (IDI) in Kampala,
Uganda, is a centre of excellence for HIV clinical care in
the country, and maintains a large observational clinic
database and a nested research cohort database on HIV-
1-infected patients registered for care. Our objective was
to assess the quality of data collection in a large HIV
observational routine clinic database by evaluating the
completeness and accuracy of recording several key data
items, including opportunistic infections (OIs), ART




From 1 January 2000 to 31 December 2007, 19,577
HIV-infected patients had registered for care at IDI, of
whom 13,099 remained in active follow up and 6421
had started ART. We focused on the subgroup of 1792
clinic patients who initiated ART over the period,
1 April 2004 to 30 April 2005. Of these, 559 patients
were also consecutively enrolled into a nested research
cohort, and 1233 patients received care through the rou-
tine clinic alone.
The electronic capture of all information onto the clinic
database began in November 2005. Key data items
recorded by clinicians at monthly follow-up visits
included: OIs, ART regimen, ART toxicities, and reasons
for treatment modification. Full blood count and CD4+
T cell count tests were performed every six months; HIV-
RNA measurements were not performed routinely, but
could be requested when treatment failure was suspected.
At IDI, clinic antiretroviral treatment is prescribed
according to World Health Organization (WHO) 2006
and Uganda Ministry of Health guidelines [8]. The first-
line ART for adults and adolescents is stavudine or
zidovudine, plus lamivudine, and nevirapine or efavirenz.
On average, 350 patients were seen daily by 10 to 15
physicians. In addition to recording details of the clinic
visit in the patients’ medical record, the selected data
items were also recorded by the physician on a clinic
monitoring summary sheet, from which they were
entered by a data administrator into an electronic
database.
Research cohort
From 1 April 2004 to 30 April 2005, in the initial phase
of the ART rollout in Uganda, 1792 patients registered
at IDI were eligible for ART initiation. Of these, 559
were consecutively enrolled into a prospective research
cohort. Reasons for not enrolling in the research cohort
included patient refusal or various exclusion criteria e.g.,
residing more than 8 km from IDI, and previous ART
exposure.
Research study visits took place every three months, in
addition to the routine monthly clinic visits. The data
items collected were similar to those at the routine
clinic visits, but standardized data collection forms were
used, and there was additional information collected on
sexual behaviour, adherence and quality of life. On aver-
age, about 15 research cohort patients were seen daily
by two trained study physicians, and data were entered
into a separate research cohort database by a dedicated
research clerical team. Full details of the research cohort
study procedures have been described previously [9].
All research participants had data from their monthly
routine clinic visits recorded on the routine clinic data-
base, but data collected at research visits on patients
co-enrolled in both the clinic and the research cohorts
were not entered onto the clinic database. All CD4 cell
counts for both the research and routine clinic patients
were carried out by a single laboratory: Makerere Uni-
versity-Johns Hopkins Uganda collaboration laboratory,
which is accredited by the College of American
Pathologists.
Outcomes and statistical analyses
We compared the baseline demographic and clinical
characteristics at ART initiation for the 559 patients
enrolled into the Research Cohort study with the 1233
patients who were initiated on ART between 1 April
2004 and 31 April 2005, but were not enrolled into the
research cohort. Categorical variables were compared
using Chi-square test, while the Mann-Whitney test was
used for the continuous variables [10]. We also exam-
ined the baseline characteristics in all 6421 patients who
had ever initiated ART at IDI to assess how representa-
tive our study populations were of all patients on ART.
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years at risk (100 PYAR), where duration of follow up
was based on time from ART initiation to date of devel-
opment of OI or death, or date of their last clinic or
research cohort study follow-up visit closest to
24 months (731 calendar days), if the patient was not
under “active” follow up [10]. For the patients who were
still under follow up as of December 31 2007, the date
of their last routine clinic visit closest to 24 months of
follow up or at the 24-month visit in the research
cohort was used. The overall incidence rate for all initial
OIs, and for each OI, was calculated.
We undertook two different comparisons of the rate
of OIs in the first 24 months following ART initiation
with the reference “gold standard” research cohort data-
base to determine the completeness and accuracy of key
data items recorded in the routine clinic database. First,
we compared the OI rate for the 559 patients in the
routine clinic database with their records in the research
cohort database (Comparison A). The second analysis
(Comparison B) compared the 1233 patients in the rou-
tine clinic database with the 559 patients in the research
cohort database in order to assess the level of underre-
porting in a larger number of patients in the clinic data-
base who were not part of a research study.
For each analysis, we compared the overall incidence
rates of the initial OI, and then the rate for the nine
most common OIs individually. These included tubercu-
losis, severe bacterial pneumonia, herpes zoster, oral and
oesophageal candidiasis, cerebral toxoplasmosis, Crypto-
coccus meningitis, genital herpes, Kaposi’s sarcoma and
an “other OI” category (Pneumocystis jirovecii pneumo-
nia, CMV retinitis, lymphoma, HIV-related anaemia,
septicaemia, chronic diarrhoea, intracerebral mass, and
pulmonary aspergillosis).
A crude percentage of underreporting of OIs in the
clinic database was calculated using two approaches: the
absolute number of OI events (only for the same 559
patients in the clinic and research databases); and the
incidence rate of OI events per 100 PYAR in the first
24 months following ART initiation. We based this on
the difference between either the number of OI events or
incidence rates reported by the research cohort database
and the routine clinic database, divided by the gold stan-
dard reference research cohort rate, multiplied by 100, as
reported by Ricci et al [11]. The second approach was
necessary as a direct comparison using absolute number
of events in the research cohort and routine clinic data-
bases was not possible for the 1233 patients, given that
the two groups of patients were not the same.
We used a further strategy to determine the complete-
ness and accuracy of data collected in the routine clinic
database by comparing the documentation (missing or
incomplete) on the summary sheets of 100 randomly
selected patients on ART in the clinic database versus
that contained in their medical records for: the nine main
OIs; ART toxicities (peripheral neuropathy, anaemia, neu-
tropaenia, rash, efavirenz-related side effects, headache,
nausea, diarrhoea, nail discolouration, lipodystrophy, lactic
acidosis, and abnormal liver function); and reasons for
change or discontinuation of ART regimen (toxicity, intol-
erance, treatment failure, and co-morbidity, e.g., tubercu-
losis). We calculated a total error rate based on the
combined number of missing and incorrect events that
were found in the clinic database after cross validation
with the information found in the patients’ medical
records.
Results
Table 1 summarizes the baseline demographic, clinical
and laboratory characteristics at ART initiation for: the
559 patients enrolled in the research cohort who
initiated ART between April 2004 and April 2005; the
1233 patients in the routine clinic database who also
initiated ART between April 2004 and April 2005, and
who were not enrolled into the research cohort; and the
6421 patients in the routine clinic database who had
ever initiated ART in the clinic up to 31 December
2007. Research cohort study patients had similar pro-
portions of women (64% vs. 62% and 64%, respectively,
p = 0.417), were slightly older (38 vs. 37 and 36 years,
p < 0.060), and had more advanced WHO stage disease
(stage 3-4 (89% vs. 79% and 71%, p < 0.0001). Overall,
the 6421 patients in the routine clinic database had a
higher CD4 count (121 cells/mm
3) compared with the
subset of patients of 1233 and 559 patients who initiated
ART over the same period: they had a similar median
CD4 count of 95 cells/mm
3 and 98 cells/mm
3,
respectively.
Table 2 shows the rates of OIs for the nine most fre-
quent first OIs in the 24 months after ART initiation
among the same 559 patients in the research cohort and
routine clinic databases, and the 1233 patients in the
routine clinic database who had initiated ART between
April 2004 and April 2005.The overall incidence rate
100 PYAR (resulting 95% confidence intervals) of the
initial OI in the 24 months after ART initiation in the
559 patients in the research cohort and clinic databases
was 24.1 (20.5-28.2) and 13.2 (10.8-16.2), respectively,
and 10.4 (9.1-11.9) for the 1233 patients in the clinic
database. This represents a 1.8- and 2.3-fold higher rate
of events in the research cohort database compared with
the same 599 patients and the 1233 patients in the rou-
tine clinic database, or a 45.2% and 56.8% rate of under-
reporting, respectively, compared with the research
cohort.
Of note, the underreporting percentage for the overall
number of initial OIs calculated using absolute number
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Female, n (%) 386 (64%) 765 (62%) 4112 (64%) 0.417
Age in years, median (IQR) 38 (33, 44) 37 (32, 43) 36 (31, 42) 0.064
WHO stage III & IV, n (%) 496 (89%) 975 (79%) 4581 (71%) <0.0001
CD4 cells/mm
3, median (IQR) 98 (21, 163) 95 (25, 168) 121 (147, 187) 0.232
ART regimen, n (%)
d4T+3TC+nevirapine 414 (74%) 727 (59%) 4224 (66%) <0.0001
ZDV+3TC+efavirenz 145 (26%) 506 (41%) 2117 (34%)
ART = Antiretroviral therapy, WHO World Health Organization, d4T = stavudine, AZT = Zidovudine, 3TC = lamuvudine, IQR = Interquartile range.
a.Based on comparison between 559 patients enrolled into the research cohort and the 1233 initiated on ART over the same time period in the clinic database,
but not enrolled into the research cohort. P value derived from Chi-square test across proportions for the categorical variables (female, WHO stage and ART
regimen) and Mann-Whitney test for continuous variables (age and CD4+ cell count).
Table 2 Number and incidence rates of opportunistic infections in the initial 24 months after ART initiation, and
percent underreporting of OI events in routine clinic versus research cohort databases for: (Comparison A) 559
patients in research cohort and same 559 patients in routine clinic databases; and (Comparison B) 559 patients in
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a 24.1 (20.5- 28.2) 91
a 13.2 (10.8 - 16.2) 206
a 10.4 (9.1 - 11.9) 40.9 45.2 56.8
Oral candidiasis 63 8.4 (6.5 - 10.7) 26 3.7 (2.5 - 5.4) 54 2.6 (2.0 - 3.3) 58.7 55.9 69.0
Severe bacterial
pneumonia
44 5.5 (4.1 - 7.6) 8 1.0 (0.5 - 2.1) 4 0.2 (0.1 - 0.5) 81.8 81.8 96.4
Tuberculosis 33 4.1 (2.9 - 5.8) 27 3.6 (2.5 - 5.3) 73 3.6 (2.8 - 4.5) 18.2 12.2 12.2
Herpes zoster 29 3.6 (2.5 - 5.2) 5 0.6 (0.3 - 1.3) 9 0.4 (0.2 - 0.8) 82.7 83.3 88.8
Cryptococcus
meningitis
7 0.8 (0.4 - 1.8) 7 0.9 (0.4 - 1.9) 16 0.7 (0.4 - 1.2) 0 +12.5
b 12.5










5 0.6 (0.2 - 1.4) 0 0.0 (0.0 - 0.0) 4 0.2 (0.1 - 0.5) 100 100 66.7
Cerebral
toxoplasmosis
2 0.2 (0.1 - 0.9) 0 0.0 (0.0 - 0.0) 4 0.2 (0.1 - 0.5) 100 100 0
Other OIs
c 8 0.9 (0.5 - 1.9) 3 0.4 (0.1 - 1.2) 11 0.5 (0.3 - 0.9) 62.5 55.5 44.4
a represents the total number of initial OI events only. In the research cohort database of 559 patients, there were 154 initial OIs, but a total of 204 events, as
116 had one OI, 28 had two OI events, and 10 had three or more OIs. In routine clinic database of 559 patients, there were 91 initial OIs, but at total of 100
events, as 87 had one OI, seven had two OI events, and one patient had three OIs. In routine clinic database of 1233 patients, there were 206 initial OIs, but a
total of 224 events, as 188 had one OI, 16 had two OI events, and two patients had three OIs.)
b OIs where there were more events reported in the clinic versus research database, representing underreporting in the research database.
c Other OIs includes Pneumocystis jirovecii pneumonia, CMV retinitis, lymphoma, HIV-related anaemia, septicaemia, chronic diarrhoea, intracerebral mass, and
pulmonary aspergillosis.
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45.2%, respectively). Similarly, the underreporting per-
centage for all the individual OIs calculated using abso-
lute number of OIs and incidence rates was similar and
w a sw i t h i n5 %o fe a c ho t h e rf o rm o s to ft h ei n d i v i d u a l
OIs, except tuberculosis and genital herpes, for which
there were a higher number of events recorded in the
routine clinic database. We therefore considered calcula-
tion of underreporting based on incidence rates as a
valid approach for the further comparison with the 1233
patients in the routine clinic database. Furthermore, the
559 research cohort participants and the 1233 patients
in the routine clinic database (n = 1233) were compar-
able in gender, age, baseline CD4 count and WHO
stage, although slightly more o ft h ec l i n i cp a t i e n t sw e r e
initiated on efavirenz-based regimens.
High percentages of underreporting of OIs in the 559
and 1233 patients in the routine clinic database were
recorded for severe bacteria pneumonia (81.8% and
96.4%, respectively), herpes zoster (83.3% and 88.8%),
oral candidiasis (55.9% and 69.0%) and oesophageal can-
didiasis (100% and 66.7%). There were low (<20%) rates
of underreporting or even better reporting in the rou-
tine clinic compared with the research cohort database
for the more serious life-threatening OIs of tuberculosis
(12.2% and 12.2%), Cryptococcus meningitis (+12.5% and
12.5%), and Kaposi’s sarcoma (+16.7% and +150%).
A l t h o u g ht h es a m en u m b e ro fp a t i e n t sw a si d e n t i f i e d
with Cryptococcus meningitis and Kaposi’s sarcoma
among the 559 patients in both databases, the incidence
rate in the clinic database was slightly higher because of
the smaller number of person years in the routine clinic
database (769.2 years versus 847.5 years in the research
cohort database). There was also a higher incidence and
233% better reporting of genital herpes in the routine
clinic than in the research cohort database.
Data audit
In the audit of quality of data on OIs, toxicities and
treatment discontinuation or modification in the routine
clinic database based on a medical records review of 100
randomly selected patients on ART, the baseline charac-
teristics at ART initiation in the 100 patients were simi-
lar to those in the overall clinic population of 1233
patients: 67% female, median age (IQR) of 37 (31, 43)
years and median CD4 (IQR) of 83 (39, 160) cells/mm
3.
Overall, the number (%) of missing and incorrect
entries in the clinic database was 124 (55%) and 27
(12%) of 127 OIs identified; 220 (49%) and 15 (3%) of
453 toxicities, and 18 (51%) and 11 (32%) of the 86
cited reasons for ART discontinuation and modification.
This gives a total error rate (comprising missing and
incorrect items) of 67% for OIs, 52% for ART-related
toxicities, and 83% and 58% for ART discontinuation
and modification, respectively. Nineteen of the 559
patients in the research cohort were included in the
data audit exercise, and we identified five OI events in
t h ea u d i t .A l lt h e s ee v e n t sh a da l r e a d yb e e nc o r r e c t l y
captured in the research cohort database, validating the
quality of data capture of OIs in the research cohort
database.
Discussion
In a large HIV observational clinic database of patients
receiving ART in Uganda, we found an overall high
level of underreporting for all OIs combined (45.1 and
56.8%), based on a comparison with a nested research
cohort that had more intensive and standardized data
collection procedures. The level of underreporting was
particularly high (>80%) for severe bacterial pneumonia,
herpes zoster and oesophageal candidiasis, using several
methods and approaches for calculating underreporting
The level of underreporting was significantly less for the
more serious life-threatening OIs, such as tuberculosis
(18.2%) and Cryptococcus meningitis (0%), which we
attributed to patients being more likely to be on
ongoing treatment and prophylaxis at their clinic visit,
which would be noted by the supervising physician.
There are several potential reasons for this underre-
porting. We examined whether this was due to a true
d i f f e r e n c ei nt h ei n c i d e n c eo fO I sa sar e s u l to fm o r e
advanced disease in the research cohort participants at
ART initiation in comparison with the 1233 patients in
the routine clinic database. However, both groups had a
s i m i l a rC D 4c o u n to f9 5c e l l s / m m
3 at ART initiation.
The underreporting was also not explained by temporal
differences in OI rates as patients in the research cohort
database initiated ART over the same time period as the
1233 patients in the routine clinic, and we also directly
compared the OI events recorded in the same 559
patients in the clinic and research cohort databases.
In the further validation exercise involving an audit of
100 randomly selected medical records, we found an
error rate of 67% for OIs, 52% for ART related toxici-
ties, and 83% and 58% for ART discontinuation and
modification, respectively. From this data audit exercise,
we also determined that underreporting of OIs on the
database was mainly due to the lack of documentation
of the key data items on the summary sheet by the
h e a l t h c a r ew o r k e ri nt h es e t t i n go fab u s yc l i n i c ,r a t h e r
than a failure of or incorrect data entry from the sum-
mary sheet onto the database. These observations are
not unique to HIV clinical observational databases, and
poor documentation of co-morbidities in databases that
collect information during the routine delivery of care
to patients has been well described in different clinic
settings, including those that are better resourced and
staffed [12-14].
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These findings have important implications for the use
and interpretation of data derived from routine HIV
observational databases for research and audit, and they
highlight the need for ongoing regular validation of key
data items in these databases. This evaluation is particu-
l a r l yt i m e l ya n dr e l e v a n tw i t ht h ee x p a n d i n gu s eo f
observational databases to assess the optimal timing of
ART initiation, and the establishment of seven regional
International Epidemiologic Databases to Evaluate AIDS
(IeDEA) networks of HIV clinical databases to address
key questions relevant to HIV care and ART manage-
ment in resource-limited settings [15].
At present, few publications based on observational
clinic data report the strategies used to validate key data
items, such as OIs, deaths, toxicities and reasons for
ART regimen change. The significant rate of loss to
follow up from ART programmes, due in part to unre-
ported mortality, highlights the limitations of conclu-
sions based just on those remaining under follow up
[16-19]. The availability in our setting of a nested
research cohort employing more intensive and standar-
dized data collection approaches within a larger clinic
observational database presented us with a unique
opportunity to assess the quality of data collection in
the clinic database. However, in most other clinics, the
quality of data collection can only be verified through
detailed and laborious review of medical notes, which
are often poorly organized, missing or illegible.
We have instituted several measures to improve the
quality of data collection in the clinic database. First,
over the past year, we have undertaken a comprehensive
retrospective audit of all OIs, ART toxicities and reasons
for ART regimen change, based on the medical records
of all 6500 patients on ART and under active follow up,
with both retrospective and real-time tracking of
patients lost to follow up for clinical outcomes and
death [20].
Second, we have introduced weekly electronic down-
loads of laboratory data, and the use of prescription
data on, for example, anti-TB medication, or fluconazole
as a means to flag unreported OIs, such as TB, oesopha-
geal candidiasis and Cryptococcus disease.
Third, a comprehensive user-friendly clinic database
reference manual has been developed to support induc-
tion and periodic training updates of all new clinic staff
in proper data collection procedures, which highlights
the key data items and codes for abstraction onto the
summary sheet. The provision of a summary sheet of
key clinically useful data, such as serial CD4 counts and
clinical events for each patient to facilitate patient care,
provides an important incentive to the healthcare
worker to maintain good data collection practices.
Finally, since October 2009, we have introduced a
daily real-time prospective monitoring of data capture of
21 key variables at each patient visit by an on-site qual-
ity assurance and control team that reviews the medical
records of all the patients seen daily at the IDI clinic
[21]. Since introduction of the programme in October
2 0 0 9 ,t h e r eh a sb e e nar e d u c t i o ni nt h ep e r c e n t a g eo f
missing and incorrect entries. We would encourage
other HIV care programmes to institute similar simple
measures to improve the quality of their patient data.
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